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Objective: A neuropathic pain (NP) questionnaire may facilitate the identiﬁcation of a neuropathic
component to osteoarthritis (OA) pain. An existing questionnaire, the painDETECT, was modiﬁed for use
in knee OA and administered to measure the prevalence and correlates of NP symptoms among adults
with this condition.
Method: Sensibility of the modiﬁed painDETECT (mPD-Q) was assessed in 20 OA subjects followed by
mail administration in an established knee OA cohort. NP symptoms were deﬁned using a previously
established, painDETECT cut-point. Correlates of NP symptoms, including OA severity (Western Ontario
and McMaster Universities Osteoarthritis Index, Von Korff Chronic Pain Grade pain subscale score),
psychological factors (Centre for Epidemiological Studies Depression Scale, Pain Catastrophizing Scale),
and concomitant medical conditions, were evaluated using logistic regression. Construct validity of the
mPD-Q was evaluated through co-administration with another NP questionnaire (S-LANSS).
Results: The mPD-Q had face and content validity. Of 259 eligible cohort members, 171 (66%) completed
the questionnaire; 28% had NP symptoms on the mPD-Q (19% among those without neurological
conditions). Independent correlates of NP symptoms were: pain intensity (adjusted odds ratio [OR]¼ 2.1
per 10 unit increase, P< 0.0001), the presence of referred back/hip pain (adjusted OR¼ 2.9, P¼ 0.024),
number of painful joints (OR¼ 1.2, P¼ 0.20) and one or more self-reported neurological condition
(OR¼ 3.0, P¼ 0.026).
Conclusions: Among older adults with chronic symptomatic knee OA, over one-quarter had NP symptoms
localized to their knees using the mPD-Q. The mPD-Q may facilitate the identiﬁcation of a neuropathic
component to pain in adults with knee OA who may beneﬁt from further evaluation and/or treatment
for NP.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA)-related pain has been attributed to local
tissue injury causing ‘nociceptive pain’1. However, cumulative data
suggest both neuropathic and nociceptive mechanisms may
contribute to the OA pain experience2e4. Therefore, there may be
a subset of people with OA who could beneﬁt from an alternative
treatment strategy, employing medications that target neuropathic
pain (NP)5. The ﬁrst step towards individualized treatment,to: Jacqueline Hochman,
Floor, Room 812B, Toronto,
ax: 416-323-7513.
man).
s Research Society International. Phowever, is the development of clinically feasible tools to identify
NP among people with symptomatic OA.
This study was based on the 1994 deﬁnition of NP as “pain
initiated or caused by a primary lesion or dysfunction of the
nervous system”6. Though a new deﬁnition has since been
proposed, it awaits validation and was not accepted when this
study was conducted7. The diagnosis of NP remains clinical, based
on a characteristic symptom proﬁle (e.g., pins and needles, electric-
shock like sensations), somatosensory abnormalities (e.g., hyper-
algesia, hypoesthesia, allodynia) and, sometimes, ancillary tests7,8.
Like other chronic pain conditions, central sensitization may
contribute to OA pain arising from chronic nociceptor stimulation
and subsequent modiﬁcation of central pain transmitting
neurons9,10. Using the 1994 deﬁnition, central sensitization could
be considered a neuropathic mechanism, causing an uncoupling ofublished by Elsevier Ltd. All rights reserved.
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activity. However, injury to nerves innervating affected joints has
not been ruled out. Indeed, some animal OA models have shown
that nerves re-innervating damaged tissues had proﬁles similar to
that in nerve-injury models, including abnormal morphology and
an excess of neuropeptides involved in pain transmission11.
Comorbid pain conditions, psychological factors and/or subclinical
neuropathies may further alter central pain processing and inﬂu-
ence the OA pain experience9,12e16. These factors may, however, go
unrecognized in musculoskeletal clinics where evaluation for NP is
not part of the standard OA assessment.
Evidence for a neuropathic component to pain in OA arises
predominately from quantitative sensory testing studies that assess
responses to experimental pain induction17e24. However, quanti-
tative sensory testing is impractical for widespread use. Thus,
capitalizing on the characteristic NP symptom proﬁle, NP ques-
tionnaires have been developed to help distinguish neuropathic
from nociceptive pain25. However, little is known about the
performance of these measures in OA. From focus groups on the
pain experience in knee OA, we found that 1/3 of participants
described their OA pain using characteristic NP descriptors26, sug-
gesting that NP questionnaires may facilitate the identiﬁcation of
a neuropathic component to OA pain.
Among existing measures, the painDETECT questionnaire
appears most appropriate for use in OA; it was developed and vali-
dated in adults with chronic low back pain (CLBP), a condition with
potentially mixed neuropathic and nociceptive pain mechanisms,
and it does not include a physical examination component27.
However, in its original form, the painDETECT does not meet some
basic principles of scale development for the intendedpopulation28:
the questions are not site-speciﬁc, but rather ask respondents to
report on their “main area of pain”; the format (e.g., crowded layout,
small font) makes self-completion difﬁcult, particularly by older
adults with visual or dexterity limitations; and the time frame for
symptom reporting is not explicit. To date, only one study has
evaluated the relationship between painDETECT scores and signs of
central sensitization in OA. Gwilym et al. self-administered the
painDETECT to 20 adults with hip OA28. Though scores above the
sample median were associated with ﬁndings suggestive of central
sensitization on quantitative sensory testing and functional
magnetic resonance imaging, the study was limited by lack of
control for confounders, in particular, concomitant back pain29.
The purpose of this study was to modify the painDETECT for use
in knee OA and to administer the modiﬁed questionnaire, the mPD-Q,
to an established knee OA cohort to evaluate: (1) the prevalence of
NP symptoms; (2) convergent construct validity of the mPD-Q
through co-administration with another NP questionnaire, the
Leeds Assessment of Neuropathic Symptoms and Signs (S-LANSS);
and, (3) potential correlates of NP symptom scores in OA.
Methods
Development and pilot testing of the modiﬁed painDETECT (mPD-Q)
The painDETECT was developed as a self-administered psycho-
metric questionnaire to distinguish NP from non-NP among people
with CLBP27. It is comprised of 7 items evaluating pain quality, one
evaluating pain pattern, and one evaluating pain radiation, which
all contribute to an aggregate score (range: e1 to 38). The pain-
DETECT has been validated against expert physician diagnosis of NP
in people with a range of chronic pain conditions including ‘typical’
NP (i.e., diabetic neuropathy) or ‘typical’ non-NP entities (i.e.,
repetitive strain injury). Overall sensitivity, speciﬁcity, and positive
predictive values using the cut-off score of 19 (NP symptoms 19),
were 85%, 80%, and 83%, respectively27.Careful evaluation of the painDETECT identiﬁed that it failed to
meet some basic principles of scale development for the intended
population28. To address these issues, the mPD-Q was developed
with the following modiﬁcations: enlargement of font, numbering
of questions, addition of an introductory ‘framing’ paragraph, and
framing of questions to ask about symptoms ‘in or around’ the
worst knee, over a speciﬁc time frame. For example, the question:
“Do you suffer from a burning sensation (e.g. stinging nettles) in
the marked areas?” was changed to:
“Please select the response that best describes the quality of
your RIGHT knee pain over the PAST MONTH. Remember that
we are using the word ‘pain’ to refer to any uncomfortable
sensation that you may or may not describe as ‘pain’.
3a. Do you suffer from a burning sensation (e.g., stinging nettles)
in or around your RIGHT knee?”Questions on pain intensity that
were not included in the overall score were removed.
The mPD-Q was pilot tested in 20 individuals with OA in self-
administered form along with a questionnaire designed to assess
respondents’ opinions regarding the measure’s understandability
and ease of use. Additional changes were made as a result of this
feedback prior to administration to the OA cohort. For example, the
question on radiation of pain was misunderstood by some who
responded by marking non-contiguous joint regions. The original
question was therefore changed from:
“Does your pain radiate to other regions of your body?”
To:
“Has your right knee pain run up or down your RIGHT leg over
the past month?”
As well, questions were separated for right and left knees. This
pilot study conﬁrmed that the mPD-Q had improved face validity
and ease of use compared to the original painDETECT in older
adults with knee OA.mPD-Q validation
Participants were recruited from an established community-
based hip/knee arthritis cohort, recruited between 1995 and 1997
from a survey of 100% of the population, aged 55þ years, in two
regions, one urban and one rural. Respondents with moderate to
severe hip or knee arthritis symptomswere selected for subsequent
follow-up (n¼ 2,411). Details regarding the recruitment have been
published elsewhere30. A validation study was performed on
a subsample of survey respondents who did and did not meet
screening criteria for hip/knee arthritis; self-reported arthritis was
validated against joint examination and radiographs. Ninety-six
percent of participants who met screening criteria for arthritis had
clinical exam signs of hip and/or knee arthritis30. The arthritis
diagnosis was OA in 86%30.
Of the 2411 original cohort members, 757 continued to partic-
ipate in 2007. For the current study, eligible participants were those
with discomfort in at least one non-replaced knee on most days
(15) over the past month. Those with self-reported physician-
diagnosed inﬂammatory arthritis, bilateral knee surgery, or factors
that interfered with questionnaire self-completion, e.g., reduced
cognition, were excluded. Ethics approval to administer a supple-
mental study questionnaire by mail was obtained from the insti-
tutional Research Ethics Board.
Standardized annual telephone interviews have been conducted
since 1999. Data were obtained from the most recent interviews
(within 12 months of the current study) on sociodemographic
Questionnaire responders  
with c hronic  kne e pain  
n /N =171/259 (66%) 
Mailed questionnaire 
N =426 
Eligible Cohort  
Members 
N =259 
Ineligible Cohort Members 
n =167 
Reasons for non - response 
Poor health n=16 
Refused n=33 
No explanation  n=39 
Questionnaire non - 
responders 
n /N = 88 /259 (3 4%) 
Original Hip/Knee  
Cohort 
N =2411 
2007 Knee  
Cohort 
N =516 
Deceased n=798 
Ineligible n=176 
Refused n=348
Unable to complete n=278 
Lost to follow - up n=54 
2007 Hip/Knee  
Cohort  
N =757 
Excluded 
n =90 
Actively participating in other  
cohort s tudy, not  
locatable/removed from cohort,   
bilateral knee replacement,  
poor eyesight, language barrier,  
poor health, poor cognition  
Fig. 1. Study sample and response to mailed questionnaire.
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( high school,> high school), OAseverity, andpsychological factors
(depressed mood and pain catastrophizing). A supplemental ques-
tionnaire was mailed to eligible cohort participants to measure NP
symptoms and collect additional information on OA symptom
severity, symptomatic joints using a joint homunculus, and speciﬁc
comorbid conditions including chronic backpainorhip pain, referred
pain to upper leg from hip or back (‘referred back or hip pain’),
ﬁbromyalgia, any other chronic pain disorders, and diabetes (DM),
neurological conditions (sciatica, shingles, post-herpetic neuralgia,
leg neuropathy, multiple sclerosis, Parkinsons disease, stroke), and
medication use (acetaminophen, nonsteroidal antiinﬂammatory
drugs [NSAIDs], opioids, NP treatments). NP treatments included
anti-depressants (e.g., tricyclic anti-depressants [TCAs], selective
serotonin, and norepinephrine reuptake inhibitors [SSRIs and SNRIs,
respectively]) and anti-convulsants (e.g., calciumchannela2-d ligand
anti-convulsants)31. Medications containing opioids were grouped
with the non-NP analgesics - acetaminophen and NSAIDs.
Participants self-completed the mPD-Q for each eligible (symp-
tomatic, non-replaced) knee. OA symptom severity was assessed
using theWesternOntario andMcMasterUniversitiesOsteoarthritis
Index (WOMAC) total and pain subscale scores32 and the Von Korff
Chronic Pain Grade (CPG) pain intensity subscale33. The WOMAC32
and CPG33 have demonstrated reliability and validity in adults
with chronic pain from the community. Higher scores on both of
these instruments indicate greater symptom severity.
Depressive symptoms were measured using the Centre for
Epidemiologic Studies Depression Scale (CES-D)34, a valid and
reliable measure of depressive symptoms in community dwelling
elderly34,35. A score 16 is considered indicative of depression35.
The Pain Catastrophizing Scale (PCS), valid and reliable in older
adults with OA, was used to measure pain catastrophizing16,36.
Higher scores indicate more pain catastrophizing36.
In the absence of a gold standard test for NP, the S-LANSS was
co-administered to assess convergent construct validity of the
mPD-Q. The S-LANSS has been validated to identify pain of
predominately neuropathic origin in patients with chronic pain of
any cause37. The S-LANSS was selected over other NP question-
naires because it has been validated in people with ‘mixed’
neuropathic and nociceptive pain, does not have a physical exam
component, and is the most widely used measure37e40. The pain-
DETECT was, however, considered more suitable for the OA pop-
ulation as it was developed in adults with CLBP. Some
pathophysiological mechanisms of pain may be shared between
peripheral OA and CLBP on the basis of facet joint OA41. In addition,
the 0e5 ordinal scale for measuring severity of NP symptoms was
preferred to the weighted binary response options on the S-LANSS.
Statistical analysis
Responders were compared to non-responders for factors that
may be associated with NP, including sociodemographic factors, OA
severity, comorbid conditions, and psychological factors to assess
for potential responder bias. An mPD-Q score was tallied for the
eligible knee(s) of each participant. When the participant had two
eligible knees, the participantmPD-Q scorewas calculated from the
mean score for the 2 knees. In absence of a known appropriate
cut-point score for NP in OA, the previously published painDETECT
cut-point was chosen27; participants with an mPD-Q score 19 in
either knee were categorized as having a ‘NP range’ score. The
proportion of knee OA cohort participants with mPD-Q scores 19
was calculated, with a 95% conﬁdence interval (CI).
For convergent construct validity testing, the Spearman’s
correlation coefﬁcient was used to compare continuous mPD-Q
scores to continuous S-LANSS scores; we hypothesized a moderateto high correlation (w0.7). Correlates of mPD-Q scores 19 were
ﬁrst assessed using bivariate analyses. Continuous variables were
compared amongst ‘NP’ and ‘non-NP’ participants using the
Student’s t-test or Wilcoxon Rank Sum Test where appropriate.
Categorical variables were assessed using the Chi-square test or
Fisher’s exact test where the cell value was <5. Signiﬁcance was
based on two-tailed tests with a 5% level of signiﬁcance. Variables
that differed signiﬁcantly among the two groups were assessed for
collinearity. Non-collinear signiﬁcant variables were considered for
multivariable logistic regression modeling.
Groups of conceptually similar variables were ﬁrst entered in
the following blocks: arthritis severity; concomitant medical/pain/
neurological conditions; and psychological factors. Within these
blocks, logistic regression was used to model the relationships of
these variables with the dichotomized mPD-Q score (<19 vs 19).
Interactions were assessed between use of NP medications and
independent factors, including each of diabetes an ﬁbromyalgia,
any neurological conditions, and scores on the CES-D and PCS. The
variable(s) contributing to the best model ﬁt were selected from
each variable block to be included in the ﬁnal multivariable logistic
regression model. Manual backwards selectionwas used to remove
independent variables with insigniﬁcant maximum likelihood
estimates (P> 0.05). A sensitivity analysis was conducted excluding
participants with self-reported neurological conditions. All statis-
tical analyses were done using SAS software, version 9.1 (SAS
Institute, Cary, North Carolina). Signiﬁcance was based on two-
tailed tests with a 5% level of signiﬁcance.
Table I
Characteristics of study participants (N¼ 171)
Characteristic n/N (%) Median (minemax)/N
Sociodemographic factors
Age (years) 76.0 (67.0e99.0)/171
Sex (% female) 132/171 (77.2)
Race (% caucasian) 154/161 (95.7)
Education (% high school) 131/165 (79.4)
Osteoarthritis severity
WOMAC e total score (/96) 53.0 (8.0e85.0)/167
WOMAC e pain score (/20) 10.1 (3.7) */168
# Painful joints (/18) 8.0 (1.0e18.0)/167
CPG pain intensity score (/100) 53.3 (6.7e100.0)/171
Concomitant conditions
Chronic back or hip pain 129/165 (78.2)
Referred back/hip pain to upper leg 73/158 (46.2)
DM 43/166 (25.9)
Fibromyalgia 20/165 (12.1)
Other pain conditionsy 47/151 (31.1)
Neurological conditionz 73/167 (43.7)
Psychological factors
CES-Depression (/60) 9.0 (0e41.0)/164
PCS score (/52) 5.0 (0e41.0)/165
Medication use
Any NP treatment 37/163 (22.7)
Non-NP analgesics 128/163 (78.5)
Chemotherapy use 5/160 (3.1)
* Mean and standard deviation is reported for the WOMAC pain subscale
(normally distributed).
y Any other pain condition (yes/no).
z Neurological conditions included stroke, leg neuropathy, sciatica, shingles,
post-herpetic neuralgia, multiple sclerosis, and Parkinson’s disease.
Table II
Frequency of responses for individual items on mPD-Q and S-LANSS questionnaires
Questionnaire items (score) Right knees
(N¼ 130)
Left knees
(N¼ 122)
mPD-Q (L1 to 38) n/N (%) n/N (%)
Knee pain pattern* (1, 0, 1)
Persistent pain with slight variations (0) 38/128 (29.7) 36/121 (30.0)
Persistent pain with pain attacks (1) 20/128 (15.6) 27/121 (22.3)
Pain attacks without pain between
them (1)
45/128 (35.2) 40/121 (33.1)
Pain attacks with pain between
them (1)
25/128 (19.5) 18/121 (14.9)
Knee pain radiation (% yes) (0, 2) 77/130 (59.2) 68/120 (56.7)
Knee pain quality (0e5)
(% moderately or more, score  3/5) n/N (%), mediany n/N (%), mediany
Burning 43/129 (33.3), 2.0 44/122 (36.1), 2.0
Tingling or prickling 37/129 (28.7), 1.0 35/122 (28.7), 1.0
Sensitivity to light touch 28/129 (21.7), 1.0 24/122 (19.7), 1.0
Pain attacks/electric shocks 65/129 (50.4), 3.0 58/122 (47.5), 2.0
Sensitivity to cold or heat 26/129 (20.2), 1.0 23/122 (18.9), 1.0
Numbness 25/129 (19.4), 1.0 30/122 (24.6), 1.0
Sensitivity to pressure 45/129 (34.9), 2.0 50/122 (41.0), 2.0
S-LANSS (0e24)z n/N (%) n/N (%)
Knee pain quality
Pins & needles, tingling
or prickling (0, 5)
55/129 (42.6) 45/118 (38.1)
Autonomic skin changes (0, 5) 38/129 (29.5) 35/118 (29.7)
Sensitive to light touch (0, 3) 47/129 (36.4) 43/118 (36.4)
Sudden pain/electric shocks (0, 2) 51/129 (39.5) 49/118 (41.5)
Burning pain (0, 1) 48/129 (37.2) 43/118 (36.4)
Self-exam items
Pins & needles, tingling or burning
on rubbing
painful area (0, 5) 18/129 (14.0) 24/118 (20.3)
Numbness or tenderness felt when
pressing on
painful area (0, 3) 50/129 (38.8) 49/118 (41.5)
* Responders selected 1 of 4 possible response options.
y Minemax score range was 0e5 for all pain quality questions.
z All S-LANSS items have binary response options.
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Study sample
Compared with the original cohort, participants with knee OA in
2007 (n¼ 516) were older, better educated, had higher income, and
were more likely to be women and residing in the rural region.
Among these knee OA cohort members, 426 were potentially
eligible to participate and were mailed study questionnaires; 259
met eligibility criteria for the current study42 and 171 (66% of 259)
completed and returned the questionnaire. (Fig. 1) Compared to
eligible non-responders, responders had lower scores for depres-
sive symptoms and pain catastrophizing.
Characteristics of the 171 study participants are summarized in
Table I. The majority were elderly (median age 76), female (77.2%),
Caucasian (95.7%), and had  high school education (79.4%).
WOMAC and CPG measures indicated moderate symptom severity.
Knee symptom duration was longstanding by virtue of original
cohort recruitment at least 10 years prior to study completion. Self-
reported comorbid conditions are shown in Table I. Median scores
on the CES-D were below the cut-point for depressive symptoms
(22% had scores 16 indicating probable depression), and median
pain catastrophizing scores were low. Almost one-quarter of study
participants (23%) reported use of medications that may be used to
treat NP and other indications, e.g., depression; of these partici-
pants (n¼ 31), the majority (84%) were using an anti-depressant
(TCA, SSRI or SNRI) that is recommended as a ﬁrst line NP
treatment.
NP questionnaire results
Frequencies of scores for individual items on the mPD-Q and
S-LANSS are shown for each eligible knee in Table II. MPD-Qscores were right-skewed. Median (min-max) mPD-Q score for
participants was 12.0 (0e38.0). Scores were similar for right and
left knees, and for participants with bilateral versus unilateral
eligible knees. Therefore, the remainder of the analysis was
performed ‘by participant’. NP range scores on the mPD-Q (19/
38) were found in 48/171 participants, with a corresponding
proportion (95% CI) of 0.28 (0.21e0.35). Excluding those with
self-reported neurological conditions, 19/98 participants, 0.19
(0.12e0.29), scored in the NP range. The correlation between
continuous mPD-Q and S-LANSS scores was moderate
(Spearman r¼ 0.73, P< 0.0001).Correlates of NP symptoms
In bivariate analyses, NP range scores on the mPD-Q were
signiﬁcantly associated with greater OA severity, a greater number
of self-reported painful joints, depressive symptoms and pain
catastrophizing, the presence of referred back or hip pain, and
self-reported neurological conditions attributable to stroke
(P¼ 0.02) and leg neuropathy/nerve damage (P¼ 0.03) (Tables III
and IV). No statistically signiﬁcant differences between partici-
pants with vs without NP were found for DM, ﬁbromyalgia or
other pain conditions, other neurological conditions, use of
medications to treat NP, use of standard treatments for OA, or
history of cancer chemotherapy. Due to collinearity between
WOMAC total and pain subscale scores, only the latter was
retained in subsequent multivariable modeling (Table III and
Table IV).
Table III
Comparison of study participants with and without NP symptoms by sociodemographic factors, OA severity, and psychological factors
Characteristics NP symptoms (N¼ 48) n/N (%)
Median (minemax)
No NP symptoms (N¼ 123) n/N (%)
Median (minemax)
P-value
Sociodemographic factors
Age (years) 75.0 (67.0e91.0)/48 76.0 (67.0e99.0)/123 NS*
Sex (% female) 38/48 (79.2) 94/123 (76.4) NS
Race (% caucasian) 42/44 (95.7) 112/117 (95.7) NS
Education (%  high school) 36/46 (78.3) 95/119 (79.8) NS
OA severity
WOMAC e total (/96) 62.0 (22.0e80.0)/47 48.0 (8.0e85.0)/120 <0.0001
WOMAC e pain (/20) 12.2 (3.4)/47 9.4 (3.5) y/121 <0.0001
# Painful joints (/18) 10.0 (2.0e17.0)/48 7.0 (1.0e18.0)/119 0.023
CPG e pain intensity (/100) 72.1 (30.0e100.0)/48 45.0 (6.7e100.0)/123 <0.001
Psychological factors
CES-Depression (/60) 15.0 (1.0e41.0)/47 6.0 (0.0e36.0)/117 <0.0001
Pain catastrophizing (/52) 11.0 (0.0e41.0)/47 4.0 (0.0e38.0)/118 0.0003
* Not signiﬁcant.
y Mean and standard deviation is reported for the WOMAC pain subscale (normally distributed).
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NP range scores were independently and signiﬁcantly associ-
ated with greater pain intensity on the CPG pain intensity subscale
(odds ratio [OR] 2.1 per 10 unit increase, P< 0.0001), a greater
number of painful joints (OR¼ 1.2, P¼ 0.020), the presence of
referred back/hip pain (OR 2.9, P¼ 0.024), and the presence of one
or more self-reported neurological condition (OR 3.0, P¼ 0.026)
(Table V). Excluding participants with neurological conditions,
model ﬁt remained stable (Table VI). NP medication use did not
modify the relationship between other variables of interest and NP
range scores.
Discussion
In a community cohort of older individuals with chronic,
symptomatic knee OA, over one-quarter had NP symptoms, local-
ized to their knees, as measured by a NP questionnaire modiﬁed for
use in knee OA. Excluding participants with self-reported neuro-
logical conditions, 19% had knee symptom scores in the NP range.
To our knowledge, this is the ﬁrst study to utilize a NP question-
naire to identify the prevalence of NP symptoms localized to knee
OA. These ﬁndings support the growing evidence that neuropathic
mechanisms may contribute to the pain experience in OA.Table IV
Comparison of study participants with and without NP symptoms by concomitant
conditions and medication use
Characteristics NP symptoms
(N¼ 48)
n/N (%)
No NP symptoms
(N¼ 123)
n/N (%)
P-value
Concomitant conditions
Chronic back or hip pain 41/46 (89.1) 88/119 (74.0) 0.034
Back/hip pain referred
to upper leg
32/44 (72.7) 41/114 (36.0) <0.0001
DM 15/46 (32.6) 28/120 (23.3) NS*
Other painy 14/40 (35.0) 33/111 (29.7) NS
Neurologicalz 29/47 (61.7) 44/120 (36.7) 0.003
Medication use
Non-NP analgesics 38/45 (84.4) 90/118 (76.3) NS
NP treatment 13/45 (28.9) 24/118 (20.3) NS
Chemotherapy 1/45 (2.2) 4/115 (3.5) NS
* Not signiﬁcant.
y Any other pain condition (yes/no).
z Neurological conditions included stroke, leg neuropathy, sciatica, shingles,
post-herpetic neuralgia, multiple sclerosis, and Parkinson’s disease.Our results are in keeping with our previous qualitative study, in
which 34% of participants spontaneously used NP descriptors to
characterize their pain26, and with estimates in other chronic pain
populations27,39,43,44. From multiple questionnaire-based studies,
the frequency of NP amongst people with CLBP has ranged from 10
to 54%27,43,45. Two recent, large studies of people with chronic pain
from any cause found the prevalence of NP to be 17% among UK
family practice patients (n¼ 6000)39 and 22% in a national pop-
ulation-based cohort in France (n¼ 7522)44. Potential explanations
for the variability in NP prevalence estimates across studies
include: (1) differential recruitment practices (estimates based on
patients recruited from specialists’ ofﬁces have been consistently
higher than those from community-based studies)37,43; (2) variable
exclusion criteria or statistical control for other potential sources of
NP (e.g., diabetic neuropathy); and (3) use of different NPmeasures.
Though a core set of discriminatory symptoms are shared among
NP questionnaires, these measures differ in inclusion of other
symptom and/or physical examination items and by scoring
systems, whichmay lead to differential classiﬁcation of peoplewith
similar pain types25. Nonetheless, these cumulative data support
the notion that neuropathic mechanisms may contribute to the
pain experience for a subset of people with chronic pain (not
limited to typical NP entities).
The mPD-Q may serve as a clinically feasible tool to aid in the
identiﬁcation of NP among adults with knee OA. From pilot testing,
the mPD-Q improved upon the painDETECT in content and face
validity and feasibility for knee OA. As hypothesized, a signiﬁcant,
moderate to high, positive correlation was observed between the
mPD-Q and the S-LANSS. Differences in scoring schemes and ques-
tionnaire items likely explain the observed correlation. The pain-
DETECT and its modiﬁed version have the advantage of measuring
the severity of NP qualities using a 0e5 ordinal scale vs the S-LANSS
which has weighted binary response options. The S-LANSS also
uniquely assesses autonomic skin changes, which is not character-
istic of OA, but likely represents complex regional pain syndrome
among the questionnaire development population46. The relation-
ship of NP range scores to self-reported neurological conditions
provides further evidence of construct validity for themPD-Q.While
this is encouraging, further construct validity testing of themPD-Q is
needed, in particular to evaluate the relationship between mPD-Q
scores and signs of NP on quantitative sensory testing.
Controlling for other factors, the likelihood of NP symptoms was
two-fold greater with every 10 point rise in CPG pain intensity
subscale score. More intense pain in OA may be associated with
a greater degree of nociceptive input to the central nociceptive
Table V
Factors associated with NP symptoms in all participants using logistic regression
modeling with mPD-Q score 19 vs <19 as dependent variable. Total sample
(N¼ 150); scores in NP range (N¼ 43)*
Independent variables Unadjusted P-value Adjustedy P-value
Odds ratio
(95% CL)
Odds ratio
(95% CL)
OA Severity
CPG e pain intensity
(per 10 unit increase)
(/100)
1.9 (1.5e2.3) <0.0001 2.1 (1.6e2.8) <0.0001
Concomitant conditions
Referred back/hip pain 4.8 (2.2e10.2) <0.0001 2.9 (1.2e7.5) 0.024
Neurological condition 2.7 (1.4e5.4) 0.004 3.0 (1.1e7.7) 0.026
# Painful joints 1.12 (1.0e1.2) 0.01 1.2 (1.0e1.3) 0.020
Adjusted R2z 0.50
C Statistic 0.90
* Complete-case analysis.
y Adjusted for: Von Korff Chronic Pain Grade pain intensity subscale, back/hip
pain referred to upper leg, self-reported neurological conditions, and number of
painful joints.
z Max rescaled R2.
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Alternatively, NP mechanisms, such as central sensitization or
disinhibition, may be synergistically or independently induced by
other factors that amplify the perception of the nociceptive stim-
ulus; these factorsmay be reﬂected in higher pain intensity scores47.
Controlling for pain intensity, the likelihood of NP symptoms at
the knee rose with each additional painful joint on the joint
homunculus, with the presence of back or hip pain referred to the
upper leg, and self-reported neurological conditions. Referred pain
from adjacent regions (the hip/back), more so than localized pain
conditions (e.g., localized back pain), may be indicative of stronger
nociceptive stimulation at these sites and greater cumulative
barrage of the central nervous system, from both the knee and
adjacent sites, increasing the risk for central sensitization and
a neuropathic component to knee OA pain9. Alternatively, referred
pain may confound NP at the knee. Similarly, individuals with
multiple painful joints may be at greater risk for central sensitiza-
tion owing to cumulative nociceptive input. Alternatively, central
sensitization may contribute to the sensation of pain at multiple
body sites. From a practical clinical perspective, a history of
multiple painful joints and/or the presence of referred back or hip
pain among patients assessed for knee OA should prompt cliniciansTable VI
Factors associated with NP symptoms among participants without neurological
conditions using logistic regression modeling with mPD-Q score 19 vs <19 as
dependent variable. Total sample (N¼ 98); scores in NP range (N¼ 16)*
Independent variables Unadjusted P-value Adjustedy P-value
Odds ratio
(95% CL)
Odds ratio
(95% CL)
OA Severity
CPG e pain intensity
(per 10 unit increase)
(/100)
1.9 (1.5e2.3) <0.0001 1.8 (1.4e3.1) 0.0004
Concomitant conditions
Referred back/hip pain 4.8 (2.2e10.2) <0.0001 2.6 (0.7e9.8) 0.16
# Painful joints 1.12 (1.0e1.2) 0.01 1.1 (0.9e1.3) 0.33
Adjusted R2z 0.39
C Statistic 0.89
* Complete-case analysis.
y Adjusted for: Von Korff Chronic Pain Grade pain intensity subscale, back/hip
pain referred to upper leg, and number of painful joints.
z Max rescaled R2.to evaluate knee pain quality as these patients may be more likely
to have a neuropathic component to their knee pain. Excluding
participants with neurological conditions,19% still had scores in the
NP range, suggesting that NP range scores were not explained
solely by co-existing neurological conditions.
Psychological factors may also contribute to central sensitiza-
tion and NP in knee OA10,12,13. According to Melzack’s neuromatrix
model, combined input from the neuromatrix (thalamus, cortex,
and limbic system) generates neuronal activity that affects pain
transmission and/or pain modulation12,13. Psychological factors
may inﬂuence neuromatrix activity through several pathways and
thereby, inﬂuence pain perception in OA13. For example, depression
may contribute to central sensitization and NP in OA through
reduced serotonin involved in descending inhibition of pain48. To
address these issues, we assessed these factors in our study.
Consistent with prior studies49,50, we found that higher scores for
each of depressive symptoms and pain catastrophizing were
associated with the presence of NP symptoms. However, when we
controlled for pain intensity, these factors were no longer signiﬁ-
cant, suggesting that depressive symptoms and/or pain cata-
strophizing may exert an inﬂuence on NP symptoms through their
effect on pain intensity. Further study is needed to assess the causal
and temporal relationships of psychological factors to the devel-
opment of NP in OA.
Strengths of our study include the focus on an unselected
community-based sample of older adults with chronic symptom-
atic knee OA, and incorporation of psychological factors in our
analyses. However, our study also has some limitations. First,
although our sample size was large relative to previous studies
examining features of NP in OA, we have insufﬁcient power to
evaluate, conclusively, the independent effects of postulated
correlates of NP symptoms. Thus, we may have missed important
relationships. However, the strong multivariable model ﬁt implies
that we identiﬁed a number of important correlates of NP symp-
toms in OA that should be considered in larger studies. Second,
compared with non-participants, our participants had lower scores
for psychological factors that have been associated with the pres-
ence and severity of NP49,50. As a result, we may have under-
estimated the prevalence of NP symptoms in the cohort. Third,
associations between responses on self-report measures may be
due, to some extent, to shared method variance e.g., participants
who report greater pain intensity may be more likely to report
stronger NP symptoms, in part, due to negative affect. However, the
relationship between pain intensity and mPD-Q scores remained
signiﬁcant after adjusting for pain catastrophizing and depressive
symptoms. Fourth, our study sample included only older adults
with longstanding OA. Thus, our results may not be generalizable to
adults who are younger/healthier or whose OA is of shorter dura-
tion. Further research is needed to determine if age and duration of
symptoms contribute to the development of NP symptoms in OA.
Finally, it remains unknownwhether scores in the NP range on the
mPD-Q reﬂect underlying mechanisms of NP. Validation of the
mPD-Q against objective measures of NP including somatosensory
testing in OA is needed, and is ongoing.
In summary, we have modiﬁed a NP questionnaire to identify
a potential neuropathic component to pain in OA. Preliminary
evaluation found the mPD-Q to be a feasible self-report tool with
face and content validity for its intended purpose and moderately
correlated to S-LANSS scores. Using the mPD-Q, we found
a substantial proportion of older adults with chronic, symptomatic
kneeOAhad symptomsofNP, localized to their knees. Theseﬁndings
suggest that neuropathicmechanismsmaycontribute to theOApain
experience. Excluding participants with self-reported neurological
conditions, OA pain intensity, number of painful joints, and the
presence of concomitant back or hip pain referred to the upper leg
J.R. Hochman et al. / Osteoarthritis and Cartilage 19 (2011) 647e654 653had high discriminative validity for distinguishing those with and
without NP range symptoms. Though further validation work is
needed, themPD-Q appears to be a clinically feasible self-report tool
for the screening of NP symptoms among adults with knee OA.
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